Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
A Phase II Study of Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Breast Cancer|HER2 Gene Mutation
DRUG: Pyrotinib
Progression-free survival (PFS), From date of first use Pyrotinib until the date of first documented progression or date of death from any cause, whichever came first, up to 36 months
Adverse events (AEs), Adverse events (AEs) and laboratory tests graded according to the NCI CTCAE (version 4.0), up to 36 months|Overall Response rates (ORR), Defined as complete response (CR) + partial response (PR), assessed based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria., up to 36 months|Clinical Benefit rate (CBR), Defined as CR+PR+stable disease (SD), assessed based on on Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria., up to 36 months|Time to Progression (TTP), Time from first use Pyrotinib to disease progression, up to 36 months|Quality of Life(QoL), Using the EORTC quality of life questionnaire QLQ-C30, up to 36 months|Overall survival (OS), Time from first use Pyrotinib to death, up to 52 months
A Phase II Study of Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer